Discussion about Several Potential Drawbacks of PEGylated Therapeutic Proteins

被引：122

作者：

Zhang, Fan ^{[1
]}

Liu, Mu-rong ^{[2
]}

Wan, Hai-tong ^{[1
]}

机构：

[1] Zhejiang Chinese Med Univ, Biol Engn Inst, Hangzhou 310000, Zhejiang, Peoples R China

[2] BIODOOR Biotechnol Co Ltd Hangzhou City Zhejiang, Hangzhou 310011, Zhejiang, Peoples R China

来源：

BIOLOGICAL & PHARMACEUTICAL BULLETIN | 2014年 / 37卷 / 03期

关键词：

PEGylation; therapeutic protein; potential risk; ACCELERATED BLOOD CLEARANCE; ACUTE LYMPHOBLASTIC-LEUKEMIA; SULFUR-HEXAFLUORIDE SONOVUE; POLYETHYLENE-GLYCOL; POLY(ETHYLENE GLYCOL); URATE OXIDASE; REPEATED INJECTIONS; MONOCLONAL-ANTIBODY; ASPERGILLUS-FLAVUS; ADVERSE-REACTIONS;

D O I：

10.1248/bpb.b13-00661

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

PEGylation changes the physical and chemical properties of the biomedical molecule, such as its conformation, electrostatic binding, and hydrophobicity, and results in an improvement in the pharmacokinetic behavior of the drug, while it also causes some disadvantages of which cannot be neglected. The available data manifests that polyethylene glycol (PEG) itself shows potential risk, such as immunogenicity of the PEG and PEG-containing vacuoles in cells observed with PEGylated biologicals. Decreased activity and heterogeneity are also the negative aspects of PEGylation. The unfavorable impacts which are brought by the PEGylation are described here with examples of modified therapeutic proteins on the market and used in the clinical trials.

引用

页码：335 / 339

页数：5

共 70 条

[1]

ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3582

[2]

Armstrong JK, 2003, BLOOD, V102, p556A

[3]

Armstrong JK, 2003, BLOOD, V102, p94A

[4]

Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients [J].